

# Live Polio Strains Soon Gone After Switch to IPV

BY BRUCE DIXON  
Chicago Bureau

Live, attenuated poliovirus vaccine strains do not persist for extended periods after the oral vaccine is replaced by the inactivated poliovirus vaccine in a developed country with a temperate climate, Q. Sue Huang, Ph.D., and colleagues reported.

The study is part of an ongoing effort to develop strategies on when and how to stop oral poliovirus vaccine (OPV) immunization once the disease is eradicated, said Dr. Huang of the Institute of Environmental Science and Research, Porirua, New Zealand (Lancet 2005;366:394-6).

The authors explained that after OPV vaccination, poliovirus is excreted by healthy children for 2-3 months and the virus' persistence in populations is limited. "Reports from several developing countries, though, indicate that circulating neurovirulent vaccine-derived poliovirus strains

**It is important that the study be repeated in tropical, developing countries where the transmission of OPV viruses is likely to be more intense.**

can be sustained for extended periods and cause poliomyelitis when population immunity is low."

When in 2002 New Zealand's immunization schedule changed from OPV to inactivated poliovirus vaccine (IPV),

Dr. Huang's team began to monitor the persistence of OPV strains excreted by the last cohorts of immunized children.

"We did systematic, population-based surveillance for OPV virus circulation and evolution before, during, and after the OPV/IPV switch with combined pediatric inpatient, acute flaccid paralysis, enterovirus laboratory, and environmental surveillance systems," the investigators said.

The first three methods targeted people most likely to be excreting poliovirus, but only environmental surveillance—obtaining composite samples from sewage systems that serve 28% of the population—was able to detect polioviruses 2 months after the OPV to IPV switch.

"Before the OPV/IPV switch, the poliovirus isolation rate was 94%. This proportion decreased after the switch, but not as rapidly as with other surveillance methods. The decline was maintained in the posttransitional period (April 2002 to April 2003) such that, after May 2002, polioviruses were only detected once every 3 months," the investigators said.

Enterovirus (pediatric inpatient) surveillance found no poliovirus isolates in stool samples 1 month after the vaccine protocol change.

Molecular sequencing traced all postswitch isolates back to OPV. "Since polioviruses evolve at a constant rate of 1% nucleotide substitutions per year, environmental isolates 6-12 months post switch with 99.7%-100% sequence homology to parental Sabin strains infer that

these viruses were derived from OPV administered 1-3 months previously," said Dr. Huang and associates.


The scientists reckoned that these viruses most likely originated in recently vaccinated children or their close contacts from an OPV-using country, which shows that New Zealand "remains vulnerable to vaccine or wild-type virus importation."

They said that it's important that the study be repeated in tropical, developing countries where transmission of OPV



viruses is likely to be more intense. "The findings of such studies are vital to formulate polio immunization policies in the postcertification era. Simultaneous global cessation of OPV after a mass immunization campaign to maximize population immunity and minimize vaccine-derived poliovirus circulation could be adopted if there is minimum risk of sustained vaccine-derived poliovirus circulation."

In an accompanying editorial, Calman MacLennan, M.D., and Jenny MacLennan, M.D., of the University of Malawi, Blantyre, said that while this study suggests that replacement of OPV with IPV can, in an environment like New Zealand's, greatly reduce, and perhaps prevent, persistence of vaccine-related polioviruses, "these findings do not address what happens if vaccination with OPV is stopped without switching to IPV and whether similar results would be obtained in tropical developing countries (Lancet 2005;366:351-3).



## What's the next cardiac risk factor you'll see today?



*Metabolic Syndrome*



*Obesity*

*Women*

*Diabetes*

*African Americans*

**For your patients at cardiac risk, refer for exercise stress testing with nuclear imaging. And when they're unable to exercise adequately, request Adenoscan pharmacologic stress. So when you see cardiac risk in your day-to-day practice, consider nuclear imaging.**

**IMPORTANT SAFETY INFORMATION**

Intravenous Adenoscan® (adenosine injection) is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.

Approximately 2.6% and 0.8% of patients developed second- and third-degree AV block, respectively. All episodes of AV block have been asymptomatic, transient, and did not require intervention; less than 1% required termination of adenosine infusion.

Fatal cardiac arrest, sustained ventricular tachycardia (requiring resuscitation), and nonfatal myocardial infarction have been reported coincident with Adenoscan infusion. Patients with unstable angina may be at greater risk.


Side effects that were seen most often included flushing (44%), chest discomfort (40%), and dyspnea (28%). Side effects usually resolve quickly when infusion is terminated and generally do not interfere with test results.

**ADENOSCAN®**  
adenosine injection



**Nuclear imaging helps you see**

©2005 Astellas Pharma US, Inc. ADS10006 7/05 www.adenoscan.com



Astellas Pharma US, Inc.